Misoo C Ellison
Overview
Explore the profile of Misoo C Ellison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giuliano A, Palefsky J, Goldstone S, Bornstein J, De Coster I, Guevara A, et al.
Hum Vaccin Immunother
. 2025 Jan;
21(1):2425146.
PMID: 39840832
Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV...
2.
Pratley R, Dagogo-Jack S, Charbonnel B, Patel S, Hickman A, Liu J, et al.
Diabetes Obes Metab
. 2020 Jul;
22(12):2276-2286.
PMID: 32700421
Aim: To assess the efficacy and safety of ertugliflozin in older patients with type 2 diabetes (T2D). Materials And Methods: This is a post hoc analysis of patients with T2D...
3.
Bouza E, Cornely O, Ramos-Martinez A, Plesniak R, Ellison M, Hanson M, et al.
Eur J Clin Microbiol Infect Dis
. 2020 Jun;
39(10):1933-1939.
PMID: 32504314
The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for Clostridioides difficile infection (CDI) significantly reduced C. difficile recurrence...
4.
Grivas P, Plimack E, Balar A, Castellano D, ODonnell P, Bellmunt J, et al.
Eur Urol Oncol
. 2020 May;
3(3):351-359.
PMID: 32423837
Background: Patients with treatment-naive advanced urothelial cancer (UC) ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population. Objective: To evaluate the safety and antitumor activity...
5.
Harrington K, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn M, et al.
J Natl Cancer Inst
. 2020 May;
113(2):171-181.
PMID: 32407532
Background: Head and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit. KEYNOTE-040 evaluated pembrolizumab vs standard of care (SOC)...
6.
Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, et al.
Curr Med Res Opin
. 2020 Apr;
36(7):1097-1106.
PMID: 32324065
To assess the efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes (T2DM). Analysis of data from Hispanic/Latino patients who participated in randomized, double-blind phase III studies....
7.
Wilcox M, Rahav G, Dubberke E, Gabryelski L, Davies K, Berry C, et al.
Open Forum Infect Dis
. 2019 Aug;
6(8).
PMID: 31375837
Background: The optimum diagnostic test method for Clostridioides difficile infection (CDI) remains controversial due to variation in accuracy in identifying true CDI. This post hoc analysis examined the impact of...
8.
Kelly C, Wilcox M, Glerup H, Aboo N, Ellison M, Eves K, et al.
Gastroenterology
. 2018 Sep;
155(4):1270-1271.
PMID: 30227108
No abstract available.
9.
Gerding D, Kelly C, Rahav G, Lee C, Dubberke E, Kumar P, et al.
Clin Infect Dis
. 2018 Mar;
67(5):649-656.
PMID: 29538686
Background: Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post...
10.
Braun P, Racich K, Ling S, Ellison M, Savoie K, Reiner L, et al.
Pediatric Health Med Ther
. 2018 Feb;
6:101-109.
PMID: 29388574
Background: Early childhood caries is the most common chronic childhood condition and largely preventable. Access to oral health preventive services (OHPS) for children at risk for caries is suboptimal and...